---
title: "Adlai Nortye Ltd. (ANL.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/ANL.US.md"
symbol: "ANL.US"
name: "Adlai Nortye Ltd."
industry: "生物技术"
---

# Adlai Nortye Ltd. (ANL.US)

| Item | Detail |
|------|--------|
| Industry | 生物技术 |
| Location | 美股市场 |
| Website | [www.adlainortye.com](https://www.adlainortye.com) |

## Company Profile

Adlai Nortye Ltd.是一家临床阶段的生物技术公司，专注于药品的研究和开发。其主要产品是 AN2025，一种全磷脂酰肌醇 3 激酶抑制剂，目前正在进行针对复发性或转移性头颈部鳞状细胞癌的第三阶段临床试验。该公司还在开发 AN0025，一种小分子前列腺素 E 受体 4 拮抗剂，旨在调节肿瘤微环境，目前正在进行针对复发性非小细胞肺癌和尿路上皮癌（在抗 PD-1/PD-L1 治疗后）、复发性三阴性乳腺癌、微卫星稳定性结直肠癌以及标准治疗后宫颈癌的第一阶段临床试验；以及 AN4005，一种口服小分子 PD-L1 抑制剂，目前正在进行第一阶段临床试验，以诱导和稳定 PD-L1 二聚体化，并干...

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -8.59 | 442/604 | - | - | - |
| PB | 46.21 | 432/604 | 2.68 | 2.33 | 1.85 |
| PS (TTM) | -49.20 | - | 36.71 | 36.71 | 17.20 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-13T05:00:00.000Z

Total Analysts: **2**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 2 | 100% |
| Overweight | 0 | 0% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 9.92 |
| Highest Target | 46.00 |
| Lowest Target | 16.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/ANL.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/ANL.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/ANL.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.